Literature DB >> 9395253

Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine.

L A Phebus1, K W Johnson, J M Zgombick, P J Gilbert, K Van Belle, V Mancuso, D L Nelson, D O Calligaro, A D Kiefer, T A Branchek, M E Flaugh.   

Abstract

LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor. It possesses little affinity for the 56 other serotonergic and non-serotonergic neuronal binding sites examined. When examined for its ability to inhibit forskolin-induced cyclic AMP accumulation in cells stably transfected with human 5-HT1F receptors, LY344864 was shown to be a full agonist producing an effect similar in magnitude to serotonin itself. After an intravenous dose of 1 mg/kg, rat plasma LY344864 levels declined with time whereas brain cortex levels remained relatively constant for the first 6 hours after injection. Oral and intravenous LY344864 administration potently inhibited dural protein extravasation caused by electrical stimulation of the trigeminal ganglion in rats. Taken together, these data demonstrate that LY344864 is a selective 5-HT1F receptor agonist that can be used to explore both the in vitro and in vivo functions of this receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9395253     DOI: 10.1016/s0024-3205(97)00885-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  30 in total

1.  No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery.

Authors:  I Bouchelet; B Case; A Olivier; E Hamel
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

Review 2.  Chemical mediators of migraine: preclinical and clinical observations.

Authors:  Saurabh Gupta; Stephanie J Nahas; B Lee Peterlin
Journal:  Headache       Date:  2011-06       Impact factor: 5.887

3.  Pharmacological profile of the 5-HT-induced inhibition of cardioaccelerator sympathetic outflow in pithed rats: correlation with 5-HT1 and putative 5-ht5A/5B receptors.

Authors:  Araceli Sánchez-Lopez; David Centurión; Erika Vázquez; Udayasankar Arulmani; Pramod R Saxena; Carlos M Villalón
Journal:  Br J Pharmacol       Date:  2003-09-22       Impact factor: 8.739

4.  5-HT1D receptors inhibit the monosynaptic stretch reflex by modulating C-fiber activity.

Authors:  Ana M Lucas-Osma; Yaqing Li; Katie Murray; Shihao Lin; Sophie Black; Marilee J Stephens; Andrew H Ahn; C J Heckman; Keith K Fenrich; Karim Fouad; David J Bennett
Journal:  J Neurophysiol       Date:  2019-01-09       Impact factor: 2.714

Review 5.  Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy.

Authors:  P Tfelt-Hansen; P De Vries; P R Saxena
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

6.  Sumatriptan elicits both constriction and dilation in human and bovine brain intracortical arterioles.

Authors:  A Elhusseiny; E Hamel
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

7.  Distribution of 5-ht(1E) receptors in the mammalian brain and cerebral vasculature: an immunohistochemical and pharmacological study.

Authors:  M T Klein; M Teitler
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 8.  5-HT(1F) Receptor agonists: a new treatment option for migraine attacks?

Authors:  Lars Neeb; Jannis Meents; Uwe Reuter
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

9.  Agonism of the 5-hydroxytryptamine 1F receptor promotes mitochondrial biogenesis and recovery from acute kidney injury.

Authors:  Sara M Garrett; Ryan M Whitaker; Craig C Beeson; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2014-05-21       Impact factor: 4.030

10.  The 5-hydroxytryptamine receptor 1F stimulates mitochondrial biogenesis and angiogenesis in endothelial cells.

Authors:  Tess V Dupre; Dorea P Jenkins; Robin C Muise-Helmericks; Rick G Schnellmann
Journal:  Biochem Pharmacol       Date:  2019-09-19       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.